3 results
Approved WMOCompleted
The primary objective is to determine the effect of intravenously administered rhAPC on HDM-LPS induced allergic lung inflammation.
Approved WMOCompleted
To demonstrate that treatment with drotrecogin alfa (activated) 24 mcg/kg/h administered as an intravenous infusion for 96 hours reduces 28 day all-cause mortality in adult patients with septic shock compared with placebo.
Approved WMOCompleted
The primary objective is to evaluate the inhalation process and the overall satisfaction with the use of the Investigational Medicinal Products (IMPs). The secondary objectives are to determine the subjective effects after pulmonary administration…